AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3521691
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg orally with naloxone intravenously
Trial: 3521691
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg orally with 0.9% saline vehicle (placebo) intravenously
Trial: 27605230
Drug: Celecoxib (COX-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib (COX-2 inhibitor) for 4 weeks postoperatively
Trial: 27605230
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no COX-2 inhibitor)
Trial: 22045673
Drug: PEG-IFNα-2a 180
RxNorm normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEG-IFNα-2a 180 μg/week for 48 weeks
Trial: 22045673
Drug: PEG-IFNα-2a 90
RxNorm normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEG-IFNα-2a 90 μg/week for 24 weeks
Trial: 22045673
Drug: PEG-IFNα-2a 90
RxNorm normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEG-IFNα-2a 90 μg/week for 48 weeks
Trial: 22045673
Drug: PEG-IFNα-2a 180
RxNorm normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEG-IFNα-2a 180 μg/week for 24 weeks
Trial: 20087260
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment with 4 cycles of carboplatine and etoposide followed by conformal radiotherapy (RT)
Trial: 20087260
Drug: Concurrent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent treatment with cisplatine and etoposide and conformal RT followed by two cycles of consolidation chemotherapy of carboplatine and etoposide
Trial: 11301846
Drug: Gemcitabine in
RxNorm normalized name: gemcitabine Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine in combination with cisplatin
Trial: 30488617
Drug: Fluvoxamine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (100 mg twice a day) plus Amantadine (100 mg daily)
Trial: 30488617
Drug: Fluvoxamine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (100 mg twice a day) plus Placebo
Trial: 26151090
Drug: Roflumilast treatment
RxNorm normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Roflumilast treatment
Trial: 9408065
Drug: Losartan (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (12.5 mg once daily)
Trial: 29764706
Drug: Rivaroxaban plus
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rivaroxaban plus an antiplatelet drug (aspirin, clopidogrel, or prasugrel)
Trial: 22554994
Drug: Brushing with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brushing with 200g force after acid and enzyme treatment
Trial: 22554994
Drug: Brushing with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brushing with 300g force after acid and enzyme treatment
Trial: 22554994
Drug: Brushing with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brushing with 400g force after acid and enzyme treatment
Trial: 16194498
Drug: Monthly home
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly home visits with intercalated phone calls from trained nursing staff
Trial: 10640164
Drug: MPA/E2C (Lunelle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPA/E2C (Lunelle Monthly Contraceptive Injection)
Trial: 25963404
Drug: Flaxseed (FS)
RxNorm normalized name: FLAXSEED
DrugBank: Flax seed (DB10708)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flaxseed (FS) 40 g daily for 4 weeks
Trial: 23889312
Drug: Adapted non‐Hodgkin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapted non‐Hodgkin lymphoma/BFM-95 therapy with high dose MTX in interim maintenance but no IT‐MTX in maintenance (Arm B1)
Trial: 23889312
Drug: Adapted non‐Hodgkin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adapted non‐Hodgkin lymphoma/BFM-95 therapy with high dose MTX in interim maintenance but no IT‐MTX in maintenance and intensification (Arm B2)
Trial: 16501393
Drug: Inpatient/Residential treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inpatient/Residential treatment
Trial: 16501393
Drug: Any Treatment
RxNorm normalized name: Acanya
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Any Treatment
Trial: 16501393
Drug: Residential/Inpatient treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Residential/Inpatient treatment
Trial: 15255797
Drug: Rectal methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal methadone (10 mg d(5)‐methadone‐HCl rectally)
Trial: 15255797
Drug: Oral methadone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral methadone (10 mg d(0)‐methadone orally)
Trial: 11359593
Drug: 0.5 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg.kg‐1 ketamine
Trial: 11359593
Drug: 0.1 mg.kg‐1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg.kg‐1 morphine
Trial: 8324915
Drug: Carbidopa 100
RxNorm normalized name: Carbidopa
DrugBank: Carbidopa (DB00190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbidopa 100 mg
Trial: 3540308
Drug: Behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral treatment program 1
Trial: 3540308
Drug: Behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral treatment program 2
Trial: 3540308
Drug: Behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral treatment program 3
Trial: 27454264
Drug: IV ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV ibuprofen alone (800 mg at induction, 800 mg every 6 hours for up to 5 days)
Trial: 27454264
Drug: IV ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV ibuprofen (800 mg at induction, 800 mg every 6 hours for up to 5 days) + IV acetaminophen (1000 mg at closure, 800 mg + 1000 mg every 6 hours for up to 5 days)
Trial: 27454264
Drug: IV ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV ibuprofen alone
Trial: 27454264
Drug: IV ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV ibuprofen + IV acetaminophen
Trial: 23845320
Drug: Graduated compression
RxNorm normalized name: oxygen
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Graduated compression stockings and subcutaneous injection of unfractionated heparin (unless contraindicated)
Trial: 23845320
Drug: Antipsychotic dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antipsychotic dosage
Trial: 19863495
Drug: 400 mL
RxNorm normalized name: Lantidra 400 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mL of milk fermented with Lactobacillus paracasei, ssp. paracasei F19, Lactobacillus acidophilus La5, and Bifidobacterium lactis Bb12 (Cultura; active)
Trial: 18829508
Drug: Docetaxel (60-75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel (60-75 mg/m² every 21 days) + Atrasentan (10 mg daily starting on day 3)
Trial: 16485512
Drug: Long-acting lipophilic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting lipophilic ACE-inhibitors
Trial: 12452468
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg gemeprost vaginal pessary every 6 hours for 18 hours
Trial: 12452468
Drug: 4 x
RxNorm normalized name: Mepilex AG 4 x 4"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 x 200 microg misoprostol tablets vaginally followed by 2 x 200 microg misoprostol tablets orally every 3 hours for 12 hours
Trial: 10599982
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (fluvastatin 40 mg/d and gemfibrozil)
Trial: 7547039
Drug: 1000 ml
RxNorm normalized name: TPN Bag 1000 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 ml preload of crystalloid solution
Trial: 7547039
Drug: 200 ml
RxNorm normalized name: Bag Top-Fill, 1200 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 ml preload of crystalloid solution
Trial: 1743319
Drug: Oral micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral micronized progesterone 300 mg
Trial: 1743319
Drug: Oral micronized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral micronized progesterone 200 mg
Trial: 1743319
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (300 mg, 200 mg, placebo)
Trial: 1743319
Drug: Endogenous E2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endogenous E2 and treatment P concentrations
Trial: 21936751
Drug: Compensation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compensation of $5 for weekly urine drug screens and self-reported drug use information, $75 for extensive assessments at weeks 4, 8, and 12
Trial: 8923916
Drug: Transvaginal ultrasonography
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transvaginal ultrasonography for evaluating endometrial grades and hormone levels (progesterone and estradiol).
Trial: 2025473
Drug: hyperbaric 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hyperbaric 0.5% bupivacaine 2.5 ml at L2-3 (n = 20)
Trial: 2025473
Drug: hyperbaric 0.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hyperbaric 0.5% bupivacaine 2.5 ml at L4-5 (n = 20)
Trial: 7044682
Drug: Low-dose heparin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose heparin prophylaxis (5000 U subcutaneously twice daily)
Trial: 24429845
Drug: Secoisolariciresinol-diglycoside (SDG)
RxNorm normalized name: anthraquinone glycoside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Secoisolariciresinol-diglycoside (SDG) at doses of 25, 50, 75, 86, and 172 mg
Trial: 22431963
Drug: Rintatolimod (Poly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rintatolimod (Poly I: C(12)U) 400 mg twice weekly
Trial: 20549835
Drug: Sublingual administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sublingual administration of asenapine (5 mg)
Trial: 20549835
Drug: Buccal administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buccal administration of asenapine (5 mg)
Trial: 20549835
Drug: Supralingual administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Supralingual administration of asenapine (5 mg)
Trial: 18257188
Drug: Acupoint-injection therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint-injection therapy with Jingming (BL 1), Yangbai (GB 14), Sibai (ST 2), Tongziliao (GB 1), bilateral Ganshu (BL 18), and compound Danggui Injection as the principal injected medicine.
Trial: 18257188
Drug: Routine western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine western medicine therapy.
Trial: 18257188
Drug: Acupoint-injection therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupoint-injection therapy
Trial: 18257188
Drug: Routine western
RxNorm normalized name: western larch pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine western medicine therapy
Trial: 16498927
Drug: Monophasic (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monophasic (120 ml at 2.5 ml/s)
Trial: 16498927
Drug: Low-high biphasic
RxNorm normalized name: DEXTRO-CHEK LOW & HIGH CALIBRATORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-high biphasic (120 ml, first 60 ml at 2 ml/s, the other 60 ml at 2.5 ml/s)
Trial: 16498927
Drug: High-low biphasic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-low biphasic (120 ml, first 60 ml at 2.5 ml/s, the other 60 ml at 2 ml/s)
Trial: 10907802
Drug: Fluoxetine (48
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (48 mg/day, range 10 mg to 60 mg)
Trial: 8887059
Drug: Interferon-alpha (IFN-alpha)
RxNorm normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Interferon-alpha (IFN-alpha) administered both topically and intramuscularly for 15 days
Trial: 1712273
Drug: Cilazapril 1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril 1.25 to 5 mg daily
Trial: 1712273
Drug: Cilazapril (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilazapril (single dose of 2.5 or 5 mg)
Trial: 30738426
Drug: Ambroxol high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol high-dose (1050 mg/day)
Trial: 30738426
Drug: Ambroxol low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ambroxol low-dose (525 mg/day)
Trial: 30738426
Drug: Ambroxol (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambroxol (both doses)
Trial: 28775306
Drug: Vaccine with
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine with four doses
Trial: 28775306
Drug: Vaccine with
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine with three doses
Trial: 21076273
Drug: HIV-1 recombinant
RxNorm normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HIV-1 recombinant canarypox vaccine (vCP1452)
Trial: 19772786
Drug: Intramuscular neridronate
RxNorm normalized name: etidronate
DrugBank: Etidronic acid (DB01077)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular neridronate (NE) 25 mg monthly
Trial: 17722830
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of Huang's Xiang Sheng Pills
Trial: 8072255
Drug: Theophylline (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (5 mg/kg body weight) administered intravenously 45 minutes before CM application.
Trial: 8072255
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline) administered intravenously 45 minutes before CM application.
Trial: 31650662
Drug: individual internet-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: individual internet-based Mindfulness-Based Cognitive Therapy (eMBCT)
Trial: 31650662
Drug: group-based face-to-face
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: group-based face-to-face Mindfulness-Based Cognitive Therapy (MBCT)
Trial: 31412947
Drug: Standard swallow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard swallow therapy (control group)
Trial: 28587977
Drug: Straight implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Straight implants (S, n=37)
Trial: 28587977
Drug: Tilted implants
RxNorm normalized name: TILT-123
DrugBank: TILT-123 (DB17519)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tilted implants (T, n=33)
Trial: 25705800
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of hydrocortisone (0.2-0.3 mg/kg body weight/day) for 10 weeks
Trial: 25705800
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of hydrocortisone (0.4-0.6 mg/kg body weight/day) for 10 weeks
Trial: 25705800
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of hydrocortisone
Trial: 23826093
Drug: 7.2 mg
RxNorm normalized name: lysine 7.2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.2 mg nicotine cartridges for 12 weeks (Group A)
Trial: 23826093
Drug: 6-week 7.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6-week 7.2 mg nicotine cartridges followed by 6-week 5.4 mg nicotine cartridges (Group B)
Trial: 21950148
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg felodipine (Plendil)
Trial: 21950148
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg felodipine (Plendil)
Trial: 11555501
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no active treatment)
Trial: 8151000
Drug: Buprenorphine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine (4 or 8 mg/day, sublingual)
Trial: 29206824
Drug: Sequential dilatation
RxNorm normalized name: phenylephrine hydrochloride Ophthalmic Solution [AK-Dilate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential dilatation
Trial: 26136585
Drug: High-polyphenol-content olive
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-polyphenol-content olive oil (HPCOO; 2.7 mg/kg)
Trial: 26136585
Drug: Low-polyphenol-content olive
RxNorm normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-polyphenol-content olive oil (LPCOO; 366 mg/kg)
Trial: 18303125
Drug: Atacicept (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atacicept (single subcutaneous or repeated every other week dose)
Trial: 16977263
Drug: Continuous Subcutaneous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Subcutaneous Insulin Infusion (CSII) with insulin lispro (n=20)
Trial: 16977263
Drug: Intravenous Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Insulin Infusion (IVII) with regular insulin (n=13)
Trial: 16977263
Drug: Intravenous Insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Insulin Infusion (IVII)
Trial: 12362961
Drug: Attention-placebo group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Attention-placebo group treatment (GT)
Trial: 9746961
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of vindesine, razoxane, and radiotherapy in 1 patient
Trial: 2532681
Drug: Rinse volumes
RxNorm normalized name: VOLUME EXPANDERS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rinse volumes of 2 ml, 5 ml, 10 ml, 15 ml, or 25 ml with air and water syringe pressures of 20/10, 20/40, 40/10, or 40/40 psi.
Trial: 2532681
Drug: 0 ml
RxNorm normalized name: TPN Bag 250 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 ml rinse volume with air and water syringe pressures of 20/10, 20/40, 40/10, or 40/40 psi.
Trial: 28955416
Drug: Amlodipine (5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (5mg once daily for 4 weeks)
Trial: 28955416
Drug: Hydrochlorothiazide (25mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (25mg once daily for 4 weeks)
Trial: 25841237
Drug: Glycopyrronium (GLY)
DrugBank: Glycopyrronium (DB00986)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrronium (GLY) 50 µg once daily + Salmeterol/Fluticasone (SAL/FP) 50/500 µg twice daily
Trial: 25841237
Drug: Tiotropium (TIO)
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium (TIO) 18 µg once daily + Salmeterol/Fluticasone (SAL/FP) 50/500 µg twice daily
Trial: 25841237
Drug: Placebo (PLA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PLA) + Salmeterol/Fluticasone (SAL/FP) 50/500 µg twice daily
Trial: 21629270
Drug: 500 ml
RxNorm normalized name: TPN Bag 500 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 ml camel milk in addition to usual care (diet, exercise, and insulin)
Trial: 21629270
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (diet, exercise, and insulin)
Trial: 16429457
Drug: Alpha tocopherol
RxNorm normalized name: alpha tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha tocopherol (AT) supplementation (134 or 268 mg/day)
Trial: 9357241
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg aspirin daily from day of positive ROT till 37 weeks of pregnancy
Trial: 31211612
Drug: Citrus aurantium
RxNorm normalized name: Citrus aurantium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Citrus aurantium aroma (neroli oil) inhalation, 30% essential oil in paraffin, administered three times a day
Trial: 25365612
Drug: 0.3 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg/kg melatonin
Trial: 22763212
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL 2% lignocaine (lidocaine)
Trial: 16444853
Drug: Enoxaparin monotherapy
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin monotherapy (1 mg/kg twice daily for 10‐18 days, then 1.5 mg/kg once daily until day 90)
Trial: 16444853
Drug: Warfarin group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin group (enoxaparin 1.0 mg/kg twice daily as a bridge to warfarin)